Abstract: Novel amidinophenol derivatives of formula (IB) and processes for the preparation thereof; compositions containing a compound of formula (IB) as active ingredient useful as antagonists of leukotine B4 and inhibitors of phospholipase A2 and/or trypsin; methods for preventing or treating diseases induced by phospholipase A2 and/or trypsin comprising administering to a patient a compound of formula (IB); and methods for treating diseases induced by leukotine B4 comprising administering to a patient a compound of formula (IB) or a known amidinophenol derivative of formula (IA)

Abstract: &ohgr;-Cycloalkyl-prostaglandin E2 derivatives of formula (I) (wherein all symbols are as defined in the description); and non-toxic salts thereof, prodrugs thereof and cyclodextrin clathrates thereof. Compounds of formula (I) strongly bind on the EP2 subtype receptor. Therefore, they are useful for prevention and/or treatment of immunological diseases (autoimmune diseases, organ transplantation etc.), asthma, abnornmal bone formation, neuronal cell death, liver damage, abortion, premature birth or retina neuropathy of glaucoma etc.

Abstract: The present invention relates to a neuropeptide Y receptor antagonist comprising a compound represented by the formula [I]: as an active ingredient.

Abstract: It is the object of the present invention to provide an iontophoresis device structure which has excellent contouring ability at its site of attachment, has very high safety, is of high quality with high product yields, and can be produced with fewer production steps to improve working efficiency and increase productivity to allow mass production at low cost. The iontophoresis device structure of the present invention has a construction provided with a cup-shaped support including a concave part, at least one electrification hole formed in the concave part, an electrode layer laid on the flat part of the rim of the concave part, and an electrolyte layer or drug-holding layer fitted into the concave part.

Abstract: The present invention relates to a compound represented by Formula [I] wherein represents an aromatic carbo- or heterocyclic ring which may have a substituent; Cy represents a mono-, bi- or tricyclic aliphatic carbocyclic group having 3 to 20 carbon atoms, which may have a substituent; represents a mono- or bicyclic aliphatic nitrogen-containing heterocyclic group having 3 to 14 carbon atoms, which may have a substituent; R1 represents a hydrogen atom, a lower alkenyl group, a lower alkynyl group, a cyclo(lower alkyl) group, an amino group, a lower alkylamino group, a di(lower alkyl)-amino group, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group or a di(lower alkyl)carbamoyl group, or a lower alkyl group which may have a substituent; and R2 represents a hydrogen atom or a lower alkyl group, a salt or ester thereof, a production process for the same, and an analge

Abstract: A sustained hair growth preparation comprising minoxidil and dipropylene glycol makes it possible to retain the absorbed minoxidil in the dermis and to increase the concentration of the minoxidil around the hair bulbs which are the hair growing sites, thereby making it possible to give a sufficient hair growth effect.

Abstract: 2-Sulfamoylbenzoic acid derivatives of general formula (I): which have both an antagonistic effect on the leukotriene D4 receptor and an antagonistic effect on the thromboxane A2 receptor and salts thereof, pharmaceuticals, anti-allergic agents and leukotrienethromboxane A2 antagonistic agents containing them as an active ingredient.

Abstract: Novel human genes usable in gene diagnosis and development of new therapeutic methods are disclosed. Specifically, human genes containing a nucleotide sequence encoding the entirety of or a portion of the amino acid sequence represented by SEQ ID NO:3, in particular, ones which are under the specific transcriptional regulation by a tumor suppressor gene p53.

Abstract: The present invention has its objects to provide a novel polypeptide having water channel activity and to a DNA sequence encoding for the polypeptide. This invention is related to a novel polypeptide having water channel activity which has the amino acid sequence, within the molecule thereof, shown in the sequence listing under SEQ ID NO:1.

Abstract: A compound represented by the general formula wherein R1 either represents a hydrogen atom or a lower alkyl group, R2 represents a hydrogen atom, an ester residue, an alkali metal or negative charge, and R3 and R4 are the same or different, and each represent a hydrogen atom or a hydrocarbonic group optionally containing hetero atom(s) selected from the group consisting of oxygen atom(s), sulfur atom(s) and nitrogen atom(s), or they are combined together with the nitrogen atom to which they bound to form a heterocyclic group, and the use thereof as an antibacterial agent.

Abstract: A novel enzyme which has an activity to release side chain carboxyl groups and ammonia from a protein by acting upon side chain amido groups in the protein. This invention relates to a method for the production of an enzyme, which comprises culturing in a medium a strain that belongs to a bacterium classified into Cytophagales or Actinomycetes and has the ability to produce an enzyme having a property to deamidate amido groups in protein, thereby effecting production of said enzyme, and subsequently collecting said enzyme from the culture mixture. It also relates to a method for the modification of protein making use of a novel enzyme which directly acts upon amido groups in protein as well as to an enzyme which has a property to deamidate amido groups in protein and a gene which encodes said enzyme.

Abstract: A process for preparing a compound represented by general formulae (5) and (6) in the following reaction scheme or salts thereof, wherein R1 represents a protective group for a nitrogen atom; R2 represents a methanesulfonyl group or p-toluenesulfonyl group; R3 represents a hydrogen atom, an aralkyl group, or an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom. The above process is useful as an industrial process for preparing intermediates of anticoagulant aromatic amidine derivatives described in Japanese Patent Application Laid-Open (kokai) No. 208946/1993.

Abstract: The present invention relates to an oligonucleotide and derivatives, hybridizable with or being complementary to at least a part of a gene encoding human CD14; and to pharmaceutical compositions, comprising the oligonucleotide or derivatives thereof as effective ingredient; and is utilisable of cure of systemic inflammatory response sydorome, etc., by the use of the pharmaceutical composition.

Abstract: (1) A human lysophosphatidic acid (human LPA) receptor, (2) a method for screening an antagonist or agonist, comprising using a human LPA receptor protein, (3) an LPA inhibitor comprising the human LPA receptor, (4) a method for producing the human LPA receptor, (5) a monoclonal or polyclonal antibody against the human LPA receptor, (6) a cDNA encoding the human LPA receptor, (7) a replication or expression vector carrying the above cDNA, and (8) a host cell transformed with the above replication or expression vector.

Abstract: A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1, and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.

Abstract: The present invention provides a stable preservation method of a powdered soft drink preparation, which includes adding 0.2 to 1.0% by weight of a calcium oxide and 0.02 to 2.0% by weight of a particulate silicon dioxide in the powdered soft drink preparation containing a carbohydrate and a sour agent as a main component. The powdered soft drink preparation of the present invention maintains the original powder state, color and taste, which are obtained immediately after the production, for a long period of time without causing comparatively rapid coagulation of powders, discoloration and change in taste at the time of preservation.

Abstract: This invention provides a compound having both IL-4 production inhibitory activity and PDE (IV) inhibitory activity, represented by formula (I): and a pharmaceutical composition or a therapeutic agent for acute and chronic inflammatory diseases and an anti-allergic or anti-inflammatory agent, each of which comprising an effective amount of the compound and a pharmacological carrier. It also provides use of the compound of formula (I) for the production of the aforementioned pharmaceutical composition or therapeutic agent for acute and chronic inflammatory diseases and anti-allergic or anti-inflammatory agent, and a method for treating acute and chronic inflammatory diseases.

Abstract: Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caus

Abstract: Azole compounds of the formula: wherein R1 is lower alkyl substituted with carboxy, etc., R2 is hydrogen or lower alkyl, R3 is aryl, etc. R4 is aryl, etc. Q is  etc., and X is O, NH or S, and its salt, which are useful as medicament.

Abstract: The present invention relates to a pharmaceutical sustained release preparation prepared by using as a sustained release ingredient a partial degradation product of the galactose of a galactoxyloglucan and a method for sustained releasing of a drug thereby. In more detail, it relates to a pharmaceutical sustained release preparation, wherein the sustained release of a drug is effected by utilizing the thermally reversible gel characteristics of the galactose-partial degradation product, which is produced by partial removal of the galactose on the side-chain of a galactoxyloglucan with an enzyme.